Cardiff Oncology, Inc.
A clinical-stage biotech company developing experimental cancer drugs, headquartered in San Diego. Its lead candidate, onvansertib, is an oral pill being tested against RAS-mutated metastatic colorectal cancer and other hard-to-treat tumors. The company began life in 2002 as a Florida shell company called Used Kar Parts, then rebranded as Xenomics, Trovagene, and finally Cardiff Oncology in 2020, when it set its sights on "turning the tide on cancer."
Bought 30.0K
Bought 24.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Pace Gary WDirector · 1 transaction | +19.5% | 4.03M | — | 30.0K | — |
| Mohindru ManiChief Executive Officer, Director · 1 transaction | — | 24.7K | — | 24.7K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +54.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.